Trial purpose
Cancer treatment
Tumor type
Haematological
Age
18+
Clinical summary
Summary
Eligible patients will be assigned to one of four phases of the study, according to their diagnosis and treatment history. The first phase is a Dose-Escalation Phase, in which participants with newly diagnosed, previously untreated, favourable or intermediate risk Acute Myeloid Leukaemia (AML) will undergo induction, consolidation, and maintenance treatment. For induction, participants will be treated with idasanutlin plus cytarabine and daunorubicin. At the investigator's discretion for consolidation, participants will either be treated with idasanutlin and cytarabine or they will undergo Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT). For maintenance, participants will be treated with single-agent idasanutlin. The second phase is a Post-Consolidation Phase, in which participants who are idasanutlin treatment-naive, have received induction and chemotherapy consolidation for AML outside of the study, and are in minimal residual disease (MRD)-positive remission after induction will be enrolled in this cohort to receive maintenance treatment with single-agent idasanutlin. In the third and fourth phase (Expansion Phase) participants with newly diagnosed, previously untreated, favourable or Intermediate-High risk AML will undergo the treatment sequence of induction, consolidation, and maintenance. For induction, participants will be treated with idasanutlin (at the recommended Phase 2 dose) plus cytarabine and daunorubicin. At the investigator's discretion for consolidation, participants will either be treated with idasanutlin and cytarabine or they will undergo allo-HSCT. For maintenance, participants will be treated with single-agent idasanutlin.
Conditions
This trial is treating people with Acute Myeloid Leukaemia
Eligibility
Inclusion
Inclusion Criteria for All Study Phases:
- Eastern Cooperative Oncology Group (ECOG) performance status ≤2
- Adequate hepatic and renal function
- For women of childbearing potential: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive measures, and agreement to refrain from donating eggs with a failure rate of <1% per year during the treatment period and for at least 6 months after the final dose of idasanutlin, cytarabine, or daunorubicin. Women must refrain from donating eggs during this same period.
- For men: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive, measures, and agreement to refrain from donating sperm that together result in a failure rate of <1% per year during the treatment period and for 6 months after the final dose of idasanutlin, cytarabine, or daunorubicin. Men must refrain from donating sperm during this same period.
Inclusion Criteria for Patients in the Dose-Escalation and Expansion Phases:
- Documented/confirmed newly diagnosed acute myeloid leukemia (AML) not previously treated according to World Health Organization (WHO)
Inclusion Criteria for Patients in the Post-Consolidation Phase:
- Documented/confirmed AML according to WHO in remission after induction, within 21 days of end of last chemotherapy consolidation cycle, and were minimum residual disease (MRD) positive at the end of induction as per local laboratory assessment
Exclusion
Exclusion Criteria for All Study Phases:
- Clinical evidence of central nervous system (CNS) leukemia
- Any Grade ≥2 non-hematologic toxicities prior to starting therapy
- Current treatment with any other investigational or commercial agents or therapies administered with the intention to treat their malignancy with the exception of hydroxyurea (HU) or 6-mercaptopurine (6-MP)
- Treatment-related AML
- Acute promyelocytic leukemia
- History of other malignancy that could affect compliance with the protocol or interpretation of results
- Any severe and/or uncontrolled medical conditions or other conditions that could affect their participation in the study, impair the ability of the investigator to evaluate the patient, or impair the patient's ability to complete the study
- Echocardiogram (ECHO) or multiple-gated acquisition (MUGA) scan showing ejection fraction ≤40%
- Non-malignant medical illnesses that are uncontrolled or whose control may be jeopardized by this study treatment, such as hereditary coagulation disorders, insulin-dependent diabetes mellitus not optimally controlled with medical management (e.g., presence of ketoacidosis), or active GI conditions affecting absorption
- Infection considered by the investigator to be clinically uncontrolled or of unacceptable risk to the patient upon the induction of neutropenia, that is, patients who are or should be on antimicrobial agents for the treatment of active infection
- Febrile patients within 72 hours of study treatment initiation
- Patients with a history of active or chronic infectious hepatitis unless serology demonstrates clearance of infection
- Patients who are unable to interrupt treatment with moderate to strong CYP2C8 inducers and inhibitors
- Patients who are unable to temporarily interrupt treatment with oral or parenteral anticoagulants/anti-platelet agents during treatment phase
- Patients who have a history of clinically significant liver cirrhosis
- Patients with extramedullary AML with no evidence of systemic involvement
- Pregnant or breastfeeding patients
- Known history of HIV-positive status
- Patients who might refuse to receive blood products and/or have a hypersensitivity to blood products
- Prior treatment with an MDM2 antagonist
- Patients with clinically relevant QTc prolongation, a family history of long QT syndrome
Exclusion Criteria for Patients in the Phase Ib Dose-Escalation Phase:
- Adverse risk patients as per European LeukemiaNet (ELN) 2017 criteria
Exclusion Criteria for Patients in Phase Ib Post-Consolidation Phase:
- Any ongoing Grade ≥2 hematologic adverse events prior to starting therapy
- Previous hematopoietic stem cell transplant (HSCT)
Exclusion Criteria for Patients in the Dose-Escalation Phase and Patients in the Favorable/Intermediate-Risk Cohort of the Expansion Phase:
- Secondary AML, defined as AML evolving from antecedent hematologic disorder (AHD)
Inclusion
- You have been diagnosed with cancer, but have not received any treatment.
- You have had a certain type of treatment or surgical procedure.
Exclusion
- You have been diagnosed with a prior or secondary type of cancer.
- You have certain types of non-cancer medical conditions.
- You have had certain treatments, surgical procedures or drugs.
- You are currently being treated on a clinical trial.
Clinical trials have complex eligibility criteria, and other criteria may apply for this trial. Ask your doctor about whether this trial could be right for you.
More information
Trial Identifiers
Information on this page is partially produced from ClinicalTrials.gov *. View further details about this trial on the registry via the links below:
Trial sponsor
Hoffmann-La Roche
Scientific Title
A Phase Ib/II Study Evaluating the Safety and Efficacy of Idasanutlin in Combination With Cytarabine and Daunorubicin in Patients Newly Diagnosed With Acute Myeloid Leukemia (AML) and the Safety and Efficacy of Idasanutlin in the Maintenance of First AML Complete Remission
Get Support
You might find it helpful to speak to someone who has 'been there before'. Our Peer Connect program can provide one-on-one phone support from someone who understands what you're going through and has clinical trials experience.
Know more about Peer Connect
If you need cancer information and practical support for yourself, a carer, family or friend, contact Cancer Council to speak with an experienced health professional on 13 11 20.
Get support
Learn more about clinical trials through this collection of resources in languages other than English.
View information